PGG glucan - Biothera

Drug Profile

PGG glucan - Biothera

Alternative Names: B-glucan PGG; Complement receptor type 3 modulator - Biothera; CR3 modulator - Biothera; Imprime PGG; Soluble beta glucan - Biothera

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Biothera
  • Developer Biothera; Dana-Farber Cancer Institute; Mayo Clinic; Merck
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Fc gamma receptor IIA modulators; Immunostimulants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Breast cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Phase I/II Chronic lymphocytic leukaemia
  • Phase I Pancreatic cancer
  • Preclinical Head and neck cancer; Myelosuppression
  • Research Follicular lymphoma
  • Suspended Infections
  • No development reported Stem cell mobilisation

Most Recent Events

  • 30 Jan 2017 Biothera terminates a phase III trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line or greater) in USA, France, Germany and Puerto Rico due to challenges in patient enrolment (NCT01309126)
  • 06 Dec 2016 Biothera and Merck plan a phase II trial for Head and neck cancer (Combination therapy, Second line therapy or greater) in Q2 2017(Biothera website, December 2016)
  • 05 Dec 2016 Biothera Pharmaceuticals and Merck expand their clinical collaboration to include Head and neck cancer (Combination therapy, Second line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top